Cognition Therapeutics (CGTX) Return on Capital Employed (2021 - 2026)
Cognition Therapeutics (CGTX) reported Return on Capital Employed of 118.31% for Q1 2026, up 21869.0% year-over-year from N/an in Q1 2025, and up 20.88% on a QoQ basis from 149.52% in Q4 2025.
Cognition Therapeutics (CGTX) has 6 years of Return on Capital Employed data on file, last reported at 118.31% in Q1 2026.
- Quarterly Return on Capital Employed rose 21869.0% year-over-year to 118.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 118.31% (up 21869.0% YoY) and the FY2025 annual result came in at 188.27%, up 6207.0% from the prior year.
- Return on Capital Employed climbed to 118.31% in Q1 2026 per CGTX's latest filing, from 149.52% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 54.48% in Q1 2022 and bottomed at 575.61% in Q2 2025.
- The 5-year median for Return on Capital Employed is 149.52% (2025), against an average of 191.09%.
- The widest annual swing landed in 2025, when Return on Capital Employed slumped 34706 bps; it then jumped 21869 bps in 2026.
- Tracing CGTX's Return on Capital Employed over 5 years: stood at 84.2% in 2022, then plunged by 125 bps to 189.28% in 2023, then tumbled by 60 bps to 303.79% in 2024, then soared by 51 bps to 149.52% in 2025, then advanced by 21 bps to 118.31% in 2026.
- Per Business Quant, the three latest CGTX Return on Capital Employed figures stand at 118.31% (Q1 2026), 149.52% (Q4 2025), and 180.45% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 21.10% |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 10.19% |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 20.34% |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -118.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -118.31% |
| Dec 31, 2025 | -149.52% |
| Sep 30, 2025 | -180.45% |
| Jun 30, 2025 | -575.61% |
| Mar 31, 2025 | -336.99% |
| Dec 31, 2024 | -303.79% |
| Sep 30, 2024 | -319.84% |
| Jun 30, 2024 | -228.55% |
| Mar 31, 2024 | -203.07% |
| Dec 31, 2023 | -189.28% |
| Sep 30, 2023 | -135.30% |
| Jun 30, 2023 | -115.77% |
| Mar 31, 2023 | -90.63% |
| Dec 31, 2022 | -84.20% |
| Sep 30, 2022 | -96.72% |
| Jun 30, 2022 | -66.05% |
| Mar 31, 2022 | -54.48% |
| Dec 31, 2021 | -64.43% |